These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31378968)

  • 1. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers.
    Gao L; Kaushik D; Ingalls K; Milner S; Smith N; Kong R
    Drugs R D; 2024 Sep; 24(3):477-487. PubMed ID: 39316278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.
    Hu M; Lee HK; To KK; Fok BS; Wo SK; Ho CS; Wong CK; Zuo Z; Chan TY; Chan JC; Tomlinson B
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1471-1478. PubMed ID: 27651239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
    Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
    Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers.
    Liu M; Wu XJ; Zhao GL; Zhang T; Xu SS; Sun YX; Qiu F; Zhao LM
    J Cardiovasc Pharmacol; 2016 Nov; 68(5):383-390. PubMed ID: 27557342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
    Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY
    Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
    Li R; Barton HA
    Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
    Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
    J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol.
    Kasten A; Cascorbi I
    Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):519-528. PubMed ID: 38809523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib.
    Long A; Yamamiya I; Valentine M; Machnes Z; Hangai N; Anderson B; Wacheck V; Gao L
    Clin Transl Sci; 2024 Sep; 17(9):e70012. PubMed ID: 39258521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.
    Sechaud R; Gu H; Rahmanzadeh G; Chiparus O; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):535-547. PubMed ID: 39110203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
    Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
    Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
    Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
    Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
    Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
    Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.